This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy or Sell Centene Stock Before Q3 Earnings Report?
by Zacks Equity Research
CNC's third-quarter earnings are likely to have been affected by lower premiums and rising medical costs.
Insights Into Molina (MOH) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Molina (MOH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Implied Volatility Surging for Molina Healthcare (MOH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Molina Healthcare (MOH) stock based on the movements in the options market lately.
Should You Buy or Hold Molina Healthcare Stock Before Q3 Earnings?
by Zacks Equity Research
MOH's third-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Earnings Preview: Centene (CNC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana and Molina Healthcare are part of the Zacks Industry Outlook article.
4 HMO Stocks to Watch Despite Continued Industry Headwinds
by Zacks Equity Research
The Medical-HMO industry is aided by rising health insurance premiums and strategic M&A moves, but faces margin pressure from high-tech costs and staffing shortages. UNH, CI, HUM and MOH are likely to navigate industry storms.
Molina (MOH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance's Pre-Q3 Earnings Analysis: Smart Buy Now or Caution Ahead?
by Zacks Equity Research
ELV's third-quarter results are likely to reflect growing operating income from the Carelon business.
UnitedHealth Pre-Q3 Earnings: Golden Opportunity or Fool's Gold?
by Kaibalya Pravo Dey
UNH's third-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Humana Stock Getting Closer to 52-Week Lows: A Buying Opportunity?
by Zacks Equity Research
HUM is facing significant challenges, including membership decline, rising costs and debt burden.
Molina Healthcare Stock Rises 15.4% in 3 Months: Should You Buy?
by Zacks Equity Research
MOH stock is expected to benefit from contract wins, rising premiums and expansion initiatives.
Do Options Traders Know Something About Molina Healthcare (MOH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Molina Healthcare (MOH) stock based on the movements in the options market lately.
Why Is Molina (MOH) Up 6.1% Since Last Earnings Report?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.
UnitedHealth (UNH) Q2 Success: A Turnaround Worth Investing in?
by Kaibalya Pravo Dey
UnitedHealth (UNH) is navigating its challenges effectively, maintaining a positive outlook for the future while demonstrating a strong commitment to its clients and shareholders.
Molina (MOH) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Molina (MOH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Molina (MOH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.27% and 0.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Centene (CNC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will High Medical Care Costs Hurt Molina's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina's (MOH) second-quarter performance is likely to have been affected by high medical care costs, partly offset by rising membership in all three businesses.
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth (UNH) Pre-Q2 Earnings: Healthy Buy or a Wait-&-See?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) second-quarter earnings are likely to have benefited from higher premiums, driven by the expansion of its commercial membership base.
Why Is Molina (MOH) Down 3.2% Since Last Earnings Report?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Brookdale (BKD) Down 3% Post Q1 Earnings: What Lies Ahead?
by Zacks Equity Research
Elevated facility operating costs and lower interest income strain Brookdale's (BKD) Q1 results, which were partly offset by favorable occupancy rates fetching improved resident fees.
Pediatrix (MD) Q1 Earnings Beat on Hospital Contract Fees
by Zacks Equity Research
Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.